Granza Bio logo

Granza Bio

Reprogramming Immunity for Target-Specific Medicines

Winter 2024Healthcare / Healthcare -> TherapeuticsSan Francisco, CA, USA7 employees
Synthetic Biology
Biotech
Healthcare
Therapeutics
Oncology

About

Granza Bio is building on the discovery of a previously unknown cytotoxic mechanism in T cells: supramolecular attack particles (SMAPs, Science 2020). This biology reveals a new modality through which cytotoxic lymphocytes deliver persistent, high-intensity killing.

Founders (2)

Ashwin Nandakumar
Founder
Ashwin Jainarayanan
Founder

Details

Status
Active
Stage
Early
Team Size
7
Regions
United States of America, America / Canada